Search Results
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate™ — PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate™ and reinforces PPL's ability to deliver life-saving
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate™ — PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate™ and reinforces PPL's ability to deliver life-saving
More news about: Piramal Pharma Solutions
Aug 17, 2026, 09:56 ET 科倫博泰宣佈2026年中期業績
BC的2期臨床研究正在進行中。其他ADC及DC產品公司亦布局了在適應症、療效及安全性方面與已上市ADC具備差異化及互補性的產品管線，包括SKB315(CLDN18.2 ADC)、SKB410 (Nectin-4 ADC)、SKB571 (新型雙抗ADC)、SKB107(RDC)、SKB103(TAA-IO雙抗ADC)和SKB565(新型雙載荷ADC)等創新資產。非DC產品
More news about: 科倫博泰
Aug 17, 2026, 07:18 ET Kelun-Biotech Announces 2026 Interim Results
ongoing.Other ADC and novel DC assetsThe Company has also built a pipeline of innovative assets that are differentiated from and complementary to approved ADCs in indications, efficacy and safety profile, including SKB315 (CLDN18.2 ADC), SKB410 (Nectin-4 ADC), SKB571 (novel bsADC),
More news about: Kelun-biotech
Aug 17, 2026, 06:44 ET HenliusとSandoz、バイオシミラー・プラットフォームのグローバルな価値を最大限に引き出すための戦略的提携を締結
加速しています。これと並行して、PD-L1 ADC「HLX43」や新規エピトープを標的とする抗HER2モノクローナル抗体「dulpatatug（HLX22）」など、将来性が期待される複数の革新的な候補薬が、世界規模での主要臨床開発を進めています。総生産能力84,000Lのバイオ医薬品製造ネットワークと、中国、欧州、米国の規制当局によるGMP認証を基盤として、Henliusは6大陸にまたがる安定したグローバル供給体制を確立しています。患者中心の使命を指針として、Henliusは、未充足の医療ニーズへの対応に注力し続け、科学的イノベーションを意義ある臨床的価値と患者へのアクセスへと結びつけ、世界のバイオ医薬品エコシステムに持続的に貢献しています。Henliusについてさらに詳しく知りたい方は、
More news about: Henlius
Aug 17, 2026, 00:08 ET Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stagesBased on the initial arrangements, the total invoiced amount expected to be achieved by Henlius
More news about: Henlius
Aug 17, 2026, 00:00 ET 復宏漢霖與山德士達成戰略合作，加速釋放生物類似藥全球價值
項臨床研究。核心產品H藥 漢斯狀® （斯魯利單抗，歐洲商品名：Hetronifly® ）作為全球首個獲批一線治療小細胞肺癌和首個獲批胃癌圍術期適應症的抗PD-1單抗，正加速全球佈局，已在全球超50個市場獲批上市；同時，多款潛力創新資產，包括PD-L1 ADC HLX43及新表位HER2單抗HLX22（通用名：dulpatatug）正全面推進全球關鍵性臨床研究。依托通過中、歐、美三地GMP認證的生產體系，復宏漢霖已建成總產能達84,000升的生物藥生產平台，形成覆蓋全球六大洲的穩定供應網絡。未來，復宏漢霖將始終堅持以患者為中心，聚焦未滿足的臨床需求，持續推動創新成果向臨床價值與患者可及轉化，在全球生物醫藥創新生態中創造長期而穩健的價值。
More news about: 復宏漢霖
Aug 14, 2026, 07:45 ET TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Inhibitors (Bi-specific ADCs)2H 2026: Presentations at key scientific meetings2H 2026: Initiation of ADC in vivo POC studiesSummary of Financial Results for the Second Quarter 2026Cash and cash equivalents of $1.0
More news about: TuHURA Biosciences, Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
call.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Aug 12, 2026, 10:31 ET CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
Development, Pharmacyclics (an AbbVie Company), Incyte Corporation, Novartis, Jazz Pharmaceuticals, Autolus Therapeutics, Syndax Pharmaceuticals, Cellectis, ADC Therapeutics, Wugen, Servier, Allogene, Amgen, Astellas Pharma, Gilead Sciences, Syndax, Incyte, Orca Biosystems, and others.
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
for squamous NSCLC, and established a new benchmark for clinical benefit.Currently, ivonescimab stands as the cornerstone of Akeso's IO2.0 + ADC2.0 strategy. We are advancing a portfolio of highly differentiated therapies that continue to elevate and reshape the global treatment landscape in major
More news about: Akeso, Inc.
Aug 11, 2026, 00:20 ET 雅特力亮相 D Forum 2026 -- AT32 MCU 驅動邊緣智慧，躍進「芯」紀元
解決方案。今年，AT32F435/437 系列新增 7x7 mm BGA100 小尺寸封裝，兼具高效能運算與豐富周邊資源，更適合空間受限的靈巧手、機器人關節及其他高密度控制模組。針對機器人關節控制，AT32M416 馬達控制 MCU 整合 CAN-FD、高解析 PWM、12-bit ADC、DSP/FPU 與磁編碼器回授，可提供高精度閉迴路控制，適用於人形機器人、四足機器人及智慧自動化設備。3. 高速馬達驅動 : AI資料中心伺服器散熱風扇伺服器散熱風扇方案在QFN32
More news about: 雅特力科技股份有限公司
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
RISE3 trial in focal epilepsy remain on track for 2H 2026.New clinical data with BHV-1530, an FGFR3-directed ADC using a novel TopoIx payload, being presented at ESMO in October 2026; new Phase 1 data will provide clinically meaningful update to early Phase 1 data
More news about: Biohaven Ltd.
Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumours, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumours, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 00:05 ET Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types.In the ADC space, Akeso has built a differentiated
More news about: Akeso, Inc.
Aug 06, 2026, 08:00 ET Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs. Whitehawk's ADC platform leverages CPT113 as the core linker-payload technology, adding its own proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation
More news about: Whitehawk Therapeutics, Inc.
Aug 06, 2026, 07:30 ET ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and
More news about: ADC Therapeutics SA
Aug 06, 2026, 07:00 ET 再鼎醫藥公佈2026年第二季度財務業績及近期公司進展
預計於2026年下半年報告用於健康志願者的全球1/1b期研究單次遞增劑量（SAD）部分的初步首次人體數據，包括藥代動力學（PK）、半衰期、藥效動力學生物標誌物（包括pSTAT6）和安全性。繼續開展用於特應性皮炎患者的1/1b期研究多次遞增劑量（MAD）部分的入組。MAD部分的初步臨床數據預計將於2027年上半年獲得。ZL-6201（LRRC15 ADC）預計於2027年上半年提供評估ZL-6201用於肉瘤和特定腫瘤患者的全球1a/b期研究劑量遞增部分的主要結果。ZL-1222（PD-1/IL-12）
More news about: 再鼎醫藥
Aug 06, 2026, 01:54 ET 復星國際榮膺《全球銀行與金融評論》三項大獎，ESG、企業社會責任及品牌實力再獲國際權威認可
科技創新成果惠及最需要的人群。復星旗下健康產業始終秉承為更多患者帶來治癒希望的初心，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，並積極拓展慢病及罕見病，打造具有長期競爭力的產品管線。持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術，取得了一系列惠及全球患者的突破性成果：漢斯狀®作為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘個國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。與此同時，復星醫藥致力於
More news about: 復星
Aug 05, 2026, 08:00 ET SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
BL-M14D1 is an investigational DLL3-targeted antibody-drug conjugate (ADC) built on SystImmune's proprietary brengitecan platform and is being developed globally for the treatment of small cell lung cancer and other neuroendocrine
More news about: SystImmune, Inc.
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
upcoming medical congress.DeLLphi-310, a Phase 1b study of IMDELLTRA in combination with YL201, a B7-H3 targeting antibody-drug conjugate (ADC), with or without a PD-L1 inhibitor, has completed enrollment of patients with ES-SCLC.DeLLphi-311, a Phase 1b study of IMDELLTRA in combination
More news about: Amgen
Aug 04, 2026, 08:30 ET AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for
More news about: AsymBio
Aug 04, 2026, 08:00 ET AI and Refresh Cycles Reenergize Network Security Hardware Market, According to Dell'Oro Group
spending on Network Security hardware is forecast to exceed $90 B during 2025–2030. Hardware revenue—comprising physical Firewall, SWG Appliance, WAF, and ADC appliances—is projected to achieve a seven percent compound annual growth rate (CAGR) during 2025–2030, up from 3.8 percent during 2020–2025.
More news about: Dell'Oro Group
Aug 04, 2026, 06:00 ET IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
with the combination or observation. The primary endpoint of the trial is relapse-free survival. ADC / DDR combinationsIDE849 (DLL3 TOP1 ADC): IDEAYA's partner in China, Jiangsu Hengrui Pharmaceuticals (Hengrui), plans to provide a clinical data update from
More news about: IDEAYA Biosciences, Inc.